Investment area

Venture Investments


North America

Date of investment

July 2019

Glycomine focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. There are 100 known glycosylation disorders. Glycomine’s lead drug, GLM101, is designed to address the largest congenital disorder of glycosylation, PMM2-CDG, through mannose-1-phophate replacement therapy.

Visit site